Navigation Links
ERT Reports Fourth Quarter and Full Year 2008 Results
Date:2/26/2009

Q4 2008 Net Revenues - $30.1 million vs. $28.9 million in Q4 2007 - a 4.0% increase

Q4 2008 Diluted Net Income per Share - $0.11 vs. $0.10 in Q4 2007 - a 10.0% increase

Q4 2008 New Bookings of $45.1 million vs. $39.2 million in Q4 2007 - a 15.1% increase

2008 Net Revenues -- $133.1 million vs. $98.7 million in 2007 - a 34.9% increase

2008 Diluted Net Income per Share of $0.48 vs. $0.29 in 2007 - a 65.5% increase

2008 New Bookings of $187.2 million vs. $138.6 million in 2007 - a 35.1% increase.

PHILADELPHIA, Feb. 26 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (ERT) (Nasdaq: ERES), a leading provider of centralized ECG, eClinical technology, ePRO and other services to the pharmaceutical, biotechnology, medical device, and related industries, announced today results for the fourth quarter of 2008 and the twelve-month period ended December 31, 2008. Unless otherwise noted, all growth numbers refer to changes from the same period a year ago.

Highlights of the fourth quarter and the year were:

  • Net revenues were $30.1 million for the fourth quarter of 2008, a 4.0% increase from the fourth quarter of 2007. Net revenues for the full year 2008 were a record $133.1 million, up 34.9% from 2007.
  • Covance Cardiac Safety Services (CCSS) revenues, all of which related to acquired backlog, were $1.9 million in the fourth quarter of 2008 compared to $1.5 million in the prior year's quarter and were $10.1 million for the full year 2008 compared to $1.5 million in the prior year.
  • Gross margin percentage in the fourth quarter increased to 57.3% from 52.6% in the prior year's quarter. The gross margin percentage for the full year was 55.8%, up from 50.7% in 2007.
  • Operating income margin percenta
    '/>"/>

SOURCE eResearchTechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical ... that the Company closed its previously announced private ... Jack W. Schuler , Birchview Fund LLC and ... before offering expenses.  The proceeds will be used ... Under the terms of the private placement, ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... series is designed to introduce cutting edge ... users and partners of platform upgrades. This ... benefits; empowering users in their quest to ... tools. , According to SoundConnect’s Marketing Manager, ...
(Date:12/24/2014)... The report expects global cell isolation and ... also provides a carefully analyzed data about the vital ... market. , Full Copy of Report @ http://bit.ly/1yUxy0T ... for cell expansion will keep witnessing growth at an ... to be driven by rapid technological advancements, government funding ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... ATLANTA, April 4, 2011 CryoLife, Inc. (NYSE: ... processing company, announced today that it has filed ... (FDA) to begin clinical trials for the purpose of obtaining ... control bleeding during surgical procedures or following traumatic injuries. ...
... ORLEANS, April 4, 2011 Orexigen ® ... additional data that showed that overweight and obese ... SR) maintained normal 24-hour circadian patterns over one ... ambulatory blood pressure monitoring (ABPM) sub-study of the ...
... (NASDAQ: OMER ), a biopharmaceutical company committed ... bleeding and disorders of the central nervous system, today ... executive officer, is scheduled to present at the 10th ... City this week.  The presentation is scheduled for Tuesday, ...
Cached Biology Technology:CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 2CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 3CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 4Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 2Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 3Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring 4
(Date:12/22/2014)... Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... security consultant, Apollo Robbins for the 2015 ... Apollo Robbins will be ... , 2015, demonstrating some of his famous theft techniques ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... and FRAMINGHAM, Mass. , Feb. ... and TruTouch Technologies, Inc. today announced that they have signed ... biometric test in the US.  The workplace sobriety assurance solution ... quickly and accurately measures alcohol consumption. This is simply done ...
... in the H5N1 avian influenza virus that affects the pH ... its capacity to infect ducks and enhances its capacity to ... today in the Journal of Virology . ... of a virus in one host species, tissue, or cell ...
... 2013 -- A range of new and promising targeted ... be presented during the 11th International Congress on Targeted ... event, which is organised by NDDO Education Foundation, is ... Cancer Institute. Over 500 oncologists and scientists ...
Cached Biology News:Psychemedics & TruTouch Announce US Sales/Marketing Distribution Agreement For TruTouch Technologies' Rapid Optical Alcohol Detection & Biometric Test 2Psychemedics & TruTouch Announce US Sales/Marketing Distribution Agreement For TruTouch Technologies' Rapid Optical Alcohol Detection & Biometric Test 3Psychemedics & TruTouch Announce US Sales/Marketing Distribution Agreement For TruTouch Technologies' Rapid Optical Alcohol Detection & Biometric Test 4Mutation altering stability of surface molecule in acid enables H5N1 infection of mammals 2Mutation altering stability of surface molecule in acid enables H5N1 infection of mammals 311th International Congress on Targeted Anticancer Therapies 2
... D kit is an enzymeimmunoassay intended ... D (25-OH D) and other hydroxylated ... Our patented DIRECT assay technology eliminates ... centrifugation and therefore facilitates automation on ...
... A multi-purpose, high gel-strength agarose suitable ... techniques, from conventional constant field to Pulsed ... high gel strength and exclusion limits, Multi ... with reduced running times. This in turn ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Rabbit polyclonal to L Kynurenine ( Abpromise for all tested applications). Antigen: Synthetic peptide L Kynurenine conjugated to a protein carrier. Entrez Gene ID: 8942 Swiss Protein ID...
Biology Products: